The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000673347p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
30/04/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
5/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Skin Cancer UNCUT: Beyond 'if in doubt, cut it out'. A randomised controlled trial of adjunctive in vivo reflectance confocal microscopy for skin cancer diagnosis.
Scientific title
Skin cancer UNCUT: Beyond 'if in doubt, cut it out'. A randomised controlled trial of adjunctive in vivo reflectance confocal microscopy for skin cancer diagnosis
Additional trial identifiers [1] 315118 0
None
Universal Trial Number (UTN)
Trial acronym
Skin UNCUT
Related trial records

Health condition
Health condition(s) studied:
Melanoma 341506 0
Basal Call Carcinoma (BCC) 341507 0
Condition category
Condition code
Cancer 337585 337585 0 0
Malignant melanoma
Public Health 337950 337950 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
All enrolled participants will undergo cutaneous confocal microscopy (CM), the study diagnostic intervention. CM will be performed by the site investigator and is expected to take up to 15 minutes. CM is a microscope applied to the skin that produces horizontal two-dimensional grey-scale digital images of the superficial skin with cellular resolution equivalent to conventional histology with a field of view of 8x8 mm. Confocal images will be reviewed and reported on by one of four expert confocalists within 2-7 days of image acquisition for the intervention arm.

Randomisation will occur after the CM procedure, to maintain blinding of allocation concealment and minimise selection bias between the groups. Participant will be randomised to either the intervention or control arm.

Intervention Arm: CM Review Group - CM images will be reviewed by CM reader and participants will be allocated to either biopsy indicated or no biopsy indicated between days 2 and 7 post-randomisation.

1. Biopsy indicated: If biopsy is indicated, choice of procedure type and intent will be performed according to national guidelines, depending on lesion characteristics and site PI's discretion as per standard of care. Confocal report will not be provided to ensure blinding is maintained between those with a biopsy indicated per CM review and those who are allocated to standard of care biopsy. Participants in the CM biopsy indicated group have a follow-up for suture removal between days 13 and 49. Remaining follow-up visits are external self-reported outcomes via survey links at 3 and 12 months.

2. No biopsy indicated: If no biopsy is indicated, sites and treating clinicians will receive a confocal report, including the assignment of no biopsy and CM diagnosis. A synoptic CM report will be given to site at the end of the study after unblinding for teaching purposes.

Non-biopsied lesions will be reviewed clinically at 3 months and 12 months to check for false negatives and biopsied if there is any concern for missed malignancy according to the PI. This will include sequential clinical and dermascopic photography.

Lesions not biopsied at 12 months will be considered truly benign.

Participants in the no biopsy group will be aware of allocation. In these cases, sites, investigators and patients will receive the full CM report, including confocal features. The CM report will contain the below information:
1. Surgical biopsy assignment
- Biopsy required
- Biopsy not required
- Insufficient quality: Retake
2. Preferred confocal diagnosis

At the end of the study, after unblinding, the site will receive a full report containing:
1. Synoptic report detailing CM features of:
- Epidermis
- Dermal-Epidermal Junction (DEJ)
- Dermis
2. Annotated images
3. Confidence of diagnosis
4. Image quality assessment/artefact
Intervention code [1] 333773 0
Diagnosis / Prognosis
Description of the comparator or control
All enrolled participants will undergo cutaneous confocal microscopy (CM), the study diagnostic intervention. Randomisation will occur after the CM procedure, to maintain blinding of allocation concealment and minimise selection bias between the groups.

Participant will then be randomised to either the intervention or control arm.

Control Arm - No CM Review/Standard of Care (SOC) Group: Will consist of surgical biopsy as per standard care between days 8-28 post-randomisation. Type of biopsy will be performed according to clinical guidelines and clinical discretion based on the size, clinical provisional diagnosis and site of the lesion. Follow-up and definitive treatment of lesion when biopsy results are received will be performed according to clinical guidelines and site PI's discretion.
Control group
Active

Outcomes
Primary outcome [1] 345074 0
Ratio of unnecessary biopsies of benign lesions at 3 months post randomisation of lesions suspicious for melanoma and basal cell carcinoma by using CM review to recommend the need for surgical biopsy.
Timepoint [1] 345074 0
3 months post-randomisation
Secondary outcome [1] 460365 0
Diagnostic accuracy of remote adjunctive CM
Timepoint [1] 460365 0
3 and 12 months post randomisation
Secondary outcome [2] 460366 0
Cost-effectiveness - Health care use including total number of biopsies in each group
Timepoint [2] 460366 0
3 and 12 months post randomisation
Secondary outcome [3] 460367 0
Evaluate patient-reported outcomes (PROs) - Purpose designed patient acceptability, satisfaction & confidence questionnaire (PASC)
Timepoint [3] 460367 0
- D2-D7 - At suture removal (both arms) - 3 months post randomisation - 12 months post randomisation
Secondary outcome [4] 462138 0
Cost-effectiveness - Health care costs
Timepoint [4] 462138 0
3 and 12 months post randomisation
Secondary outcome [5] 462139 0
Cost-effectiveness - Number of unnecessary biopsies for benign lesions
Timepoint [5] 462139 0
3 and 12 months post randomisation
Secondary outcome [6] 462140 0
Cost-effectiveness - Utility based quality of life
Timepoint [6] 462140 0
3 and 12 months post randomisation
Secondary outcome [7] 462141 0
Cost-effectiveness - Quality-adjusted survival
Timepoint [7] 462141 0
3 and 12 months post randomisation
Secondary outcome [8] 462142 0
Cost-effectiveness - Incremental costs of CM review to avoid one unnecessary biopsy
Timepoint [8] 462142 0
3 and 12 months post randomisation
Secondary outcome [9] 462143 0
Cost-effectiveness - Incremental costs of CM to achieve one year of life in full health
Timepoint [9] 462143 0
3 and 12 months post randomisation
Secondary outcome [10] 462144 0
Evaluate patient-reported outcomes (PROs) - Fear of Cancer Occurrence
Timepoint [10] 462144 0
- D2-7 post randomisation - At suture removal (both arms) - 3 months post randomisation - 12 months post randomisation
Secondary outcome [11] 462145 0
Evaluate patient-reported outcomes (PROs) - Distress Scale
Timepoint [11] 462145 0
- Baseline - D2-D7 post randomisation - At suture removal (both arms) - 3 months post randomisation - 12 months post randomisation
Secondary outcome [12] 462146 0
Evaluate patient-reported outcomes (PROs) - Scar appearance (SCAR-Q)
Timepoint [12] 462146 0
- At suture removal (biopsy group only) - 3 months post randomisation (biopsy group only) - 12 months post randomisation (biopsy group only)

Eligibility
Key inclusion criteria
1. Aged 18 years or over
2. Able to provide informed consent and willing to comply with protocol requirements, including the completion of self-administered assessments of skin cancer risk factors and PROs at the designated time points
3. Able to complete questionnaires in English
4. Able to attend confocal microscopy image acquisition site
5. Able to attend follow-up appointments during weeks 1-7 and 3 and 12 months depending on arm allocation
6. Have a skin lesion identified as a potential cutaneous malignancy (including melanoma and BCC), based on clinical examination and preferably with dermoscopy by their treating medical practitioner or from the Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID) cohort study
7. One lesion for which the clinical diagnosis of confidence is 2 or 3 at the discretion of the treating clinician (diagnostic confidence score at baseline using a 3-point scale: "1 - very confident", "2 - somewhat confident" and "3 - not confident"
8. Skin lesion is located at a body site amenable to vivascope tissue coupled 1500 CM imaging
9. Only one lesion will be included per participant
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Lesion at body sites where tissue coupled CM is not amenable to CM imaging, including acral lesions, peri-ungual lesions, deep concavities (e.g. inner canthus), mucosal sites
2. Lesion types which are not evaluable with CM: ulcerated, bleeding, crusted or hyperkeratotic lesions or potential squamous cell carcinomas
3. Lesions referred for mapping/margin assessment rather than diagnosis
4. Lesions for which the clinical diagnosis of malignancy is highly certain
5. Lesions for which preferred clinical diagnosis is squamous cell carcinoma
6. Recurrent lesions, or persistent lesions which have previously been treated with cryotherapy, imiquimod, topical 5-fluorouracil, surgery, radiotherapy or other methods
7. Giant pigmented lesions of >4cm diameter
8. Lesions which cannot be biopsied at the study site
9. Participant in other clinical trial studies may be permitted only after consultation with and approval by the Trial Management Committee (TMC)

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation via REDCap
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The method of generating the allocation sequence is computerised sequence generation.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Recruitment hospital [1] 29393 0
Westmead Hospital - Westmead
Recruitment hospital [2] 29394 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 29395 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 29396 0
Townsville University Hospital - Douglas
Recruitment hospital [5] 29397 0
The Skin Hospital (Darlinghurst) - Darlinghurst
Recruitment hospital [6] 29458 0
Melanoma Dermatology (Sydney) - Wollstonecraft
Recruitment hospital [7] 29459 0
Sydney Melanoma Diagnostic Centre - Camperdown
Recruitment hospital [8] 29460 0
Sydney Confocal - Dee Why
Recruitment hospital [9] 29461 0
Cygnet Dermatology - Charlestown
Recruitment hospital [10] 29462 0
Skintel - Melbourne
Recruitment hospital [11] 29463 0
Perth Dermatology Clinic - Perth
Recruitment hospital [12] 29464 0
Wagga Wagga Base Hospital - Wagga Wagga
Recruitment postcode(s) [1] 45714 0
2145 - Westmead
Recruitment postcode(s) [2] 45715 0
5000 - Adelaide
Recruitment postcode(s) [3] 45716 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 45717 0
4814 - Douglas
Recruitment postcode(s) [5] 45718 0
2010 - Darlinghurst
Recruitment postcode(s) [6] 45776 0
2065 - Wollstonecraft
Recruitment postcode(s) [7] 45777 0
2050 - Camperdown
Recruitment postcode(s) [8] 45778 0
2099 - Dee Why
Recruitment postcode(s) [9] 45779 0
2290 - Charlestown
Recruitment postcode(s) [10] 45780 0
3004 - Melbourne
Recruitment postcode(s) [11] 45781 0
6000 - Perth
Recruitment postcode(s) [12] 45782 0
2650 - Wagga Wagga

Funding & Sponsors
Funding source category [1] 319695 0
Government body
Name [1] 319695 0
Australian Government - National Health and Medical Research Council
Country [1] 319695 0
Australia
Primary sponsor type
University
Name
The University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 322199 0
None
Name [1] 322199 0
Address [1] 322199 0
Country [1] 322199 0
Other collaborator category [1] 283903 0
Other Collaborative groups
Name [1] 283903 0
Melanoma Institute Australia
Address [1] 283903 0
Country [1] 283903 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 318252 0
Sydney Local Health District Ethics Review Committee (RPAH Zone)
Ethics committee address [1] 318252 0
Ethics committee country [1] 318252 0
Australia
Date submitted for ethics approval [1] 318252 0
30/03/2026
Approval date [1] 318252 0
Ethics approval number [1] 318252 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 143582 0
Prof Pascale Guitera
Address 143582 0
Sydney Melanoma Diagnostic Centre, Level 2, Gloucester House, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050
Country 143582 0
Australia
Phone 143582 0
+61 2 9515 8537
Fax 143582 0
Email 143582 0
Contact person for public queries
Name 143583 0
Ellen Gao
Address 143583 0
NHMRC Clinical Trials Centre, Lifehouse, Level 6, 119-143 Missenden Rd, Camperdown NSW 2050
Country 143583 0
Australia
Phone 143583 0
+61 2 9562 5000
Fax 143583 0
Email 143583 0
Contact person for scientific queries
Name 143584 0
Pascale Guitera
Address 143584 0
Sydney Melanoma Diagnostic Centre, Level 2, Gloucester House, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050
Country 143584 0
Australia
Phone 143584 0
+61 2 9515 8537
Fax 143584 0
Email 143584 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.